The term “treatment-resistant” can be incredibly worrying to hear, especially when you are living with a health condition that is seriously affecting your life. This worry is completely understandable. In a physical health context, treatment-resistant may mean that the available drugs aren’t effective against a certain infection or that a condition is becoming potentially critical.
But when treatment-resistant is used to describe depression, the term means something a little different. Treatment-resistant depression means that specific strategies tried so far haven’t produced the results they were expected to. While this can be frustrating, it does not mean that there is no hope. When depression is identified as treatment-resistant, the question is not, “Can this be treated at all?”, but rather, “Which new paths haven’t been explored yet?”
This page explores those paths, including advanced depression therapies that could change the direction of your treatment. It will cover:
Treatment-resistant depression is a clinical term used when depression hasn’t responded well to at least two different antidepressant medications.[1] Depression not responding to medication is more common than most people realize.
One review estimated that around 30% of major depressive disorder (MDD) cases are resistant to first-line treatment.[2]
But, while the term ‘treatment-resistant’ can sound like a devastating diagnosis, it’s important to know that it only describes how your depression has responded to treatments so far. It doesn’t describe a permanent quality of your condition, and it certainly doesn’t mean your depression is untreatable.
Severe depression treatment for adults often requires exploring multiple approaches before finding what works, so clinicians often expect treatment resistance in early care.
A sizeable portion of people labeled as treatment-resistant are actually “pseudo-resistant,” meaning that there may have been issues with dosage or duration of the antidepressants prescribed.[2] This doesn’t mean that mistakes have been made; rather, it may possibly mean the right dose hasn’t been found yet. The review also cites underlying diagnoses that weren’t fully accurate as a contributor to the lack of treatment success.[2]
Before looking at potential solutions for treatment resistance, it’s worth understanding why the first approach may not have produced results. In a lot of cases, the answer points toward something that can be addressed, and which your treatment team will be more than willing to explore.
The McIntyre review we touched upon above states that roughly half of people with depressive disorder are not correctly diagnosed. For example, bipolar depression misidentified as unipolar depression is one of the most common clinical misdiagnoses.[2]
Adult attention-deficit hyperactivity disorder (ADHD) masked by depressive symptoms is another condition that goes unrecognized, especially in women, due to how the condition presents in females.[3]
If your treatment team hasn’t already raised the possibility of an incomplete or mistaken diagnosis, it’s worth asking the question the next time you meet.
In some cases, people are labeled as treatment-resistant when the medication was prescribed at the wrong dose for them, or wasn’t taken long enough to reach its full effect. For example, guidelines for many antidepressants recommend at least six to eight weeks at a therapeutic dose before any conclusion on effectiveness can be made.
Research that followed thousands of adults with depression found that first-step remission was 25.5%. That number fell with each step, dropping to 13.2% at step three and 10.4% at step four.[4]
But people did continue to remit at later stages, which shows us that persistence matters, as long as each step is an adequate trial.
While medication can be effective at treating the neurochemistry of depression, it doesn’t account for the environmental factors that drive depression. If they’re still present in your day-to-day life, the medication is fighting a strong current.
Factors that contributed to your depression in the first place, whether it’s a difficult relationship or an over-demanding job, can diminish the antidepressant effects. This doesn’t mean that you should stop taking the medication, but it does mean that other problematic areas of your life may need to be strategically addressed.
Now that we’ve covered the possibilities of why depression may continue to be treatment-resistant, it’s important to understand all the potential alternatives and augmentations to first-line antidepressants. Below, we explore some of the potentially effective treatment options.
If your prescriber has suggested that a second line of medication could be useful, it’s not something to be concerned about. Clinical guidelines generally favor adding a second medication rather than switching to a different one, especially when two antidepressants haven’t worked.
One trial tested this directly by randomizing over 1500 adults to either switch antidepressants or augment with a second medication.[5]
Augmentation with aripiprazole produced the highest remission rate at nearly 28.9% compared to 22.3% for switching.[5]
Lithium augmentation has the longest research history behind it, with one analysis finding that those who had lithium added to their antidepressant course were more than twice as likely to respond compared to a placebo.[6]
This isn’t something for you to decide on alone; rather, it’s a conversation to have with your therapist and the rest of your treatment team. They can walk you through whether a second line of medication is necessary, and if so, which strategy makes the most sense for your situation.
Ketamine therapy for depression in adults is an option that has caused many raised eyebrows over the past decade, but it’s also one with a lot of promise.
Traditional antidepressants work on the serotonin system, but can take weeks to produce any effects. Ketamine based treatments, on the other hand, work on the glutamate system and can produce improvements in depressive symptoms within just 24 hours.
Esketamine is a nasal spray that received FDA approval in 2019 for treatment-resistant depression, when used alongside antidepressants.[7] In January 2025, it became one of the newest treatments for depression in adults, as the first and only FDA-approved monotherapy for treatment-resistant depression.[7]
Trials conducted against other alternative treatment-resistant depression techniques were promising, too. One trial compared IV ketamine to electroconvulsive therapy (ECT) in adults with treatment-resistant depression and found that 55.4% responded well to ketamine, compared to 41.2% for ECT.[8]
But there are downsides to ketamine treatment, which are still being worked through. Research has found that even among patients with treatment-resistant depression who initially responded well to ketamine, around 70% relapse within six months.[7]
This isn’t to say that the medication itself stops working, but there are other issues surrounding it. For example, cost is an enormous factor. Research suggests that the average annual drug cost for the first year of Esketamine treatment can range anywhere from $18,500 to $45,500.[9]
Generic ketamine, while substantially cheaper, requires supervision when administered in a clinic environment.[9] This may need to be done for up to 40 minutes, one to three times a week, which can be a problem for someone with important responsibilities.[9]
TMS uses magnetic pulses to stimulate specific areas of the brain that are involved with a person’s mood regulation. As unorthodox as it may sound, it’s non-invasive and has been FDA-approved since 2008.[10]
Research on TMS therapy and its effectiveness for depression has been consistently positive. One analysis found that people receiving TMS were more than three times as likely to respond and more than five times as likely to achieve remission. Standard treatment involves daily sessions for four to six weeks.[11]
A newer accelerated protocol developed at Stanford compresses this into five days. A randomized controlled trial of this accelerated approach found that 79% of participants achieved remission, compared to 13% in the sham group.[12] The sample was small, so the real-world numbers may be more modest, but the speed of the protocol is genuinely new ground for a non-drug treatment.
ECT is considered one of the most effective acute treatments for severe depression in adults, but it’s also one of the most misunderstood.
ECT treatment for depression was first introduced in the 1930s, but without the safety controls that exist today, it was considered a controversial practice. Nowadays, ECT bears little resemblance to the 1930’s version that still influences many people’s perception.
Research on ECT outcomes in treatment-resistant patients found remission rates of 48% in those who had failed antidepressant trials. This number rises to 65% in those without prior treatment failures.[13]
ECT is typically reserved for cases where other options haven’t worked or where the severity of the depression is life-threatening.
AMFM is here to help you or your loved one take the next steps towards an improved mental well-being.
We have explained in depth the different types of medications and alternative treatments that may be considered in certain treatment-resistant depression cases. However, it is worth noting that therapy remains a core part of treatment, especially when it’s adapted for chronic or resistant presentations.
A meta-analysis of cognitive behavioral analysis system of psychotherapy (CBASP), a form of therapy developed for persistent depressive disorder treatment and chronic depression, found that it outperformed standard care with moderate-to-high effect sizes.[14] When CBASP was combined with medication, the results were better than medication alone.[14]
The point here is that therapy for treatment-resistant depression may need to look different from standard cognitive behavioral therapy. Chronic depression treatment strategies like CBASP exist for exactly this reason, and asking your provider about them is a reasonable step.
While we covered several treatment alternatives on this page, it’s worth revisiting something we touched on earlier.
The research is clear that a large proportion of cases labeled as treatment-resistant depression involve missed diagnoses or medication trials that weren’t given a fair chance.
Bipolar depression mistaken for unipolar depression and adult ADHD buried beneath depressive symptoms are two of the most common examples. Either one of these can produce what appears to be treatment resistance when the real problem is that the treatment was aimed at the wrong target.
The question worth thinking about, and the point worth raising with your team, is whether they have looked at this from a different angle. A fresh clinical perspective, especially from a team experienced in complex presentations, can sometimes bring more clarity than you may think.
A Mission For Michael (AMFM) provides treatment for adults experiencing various conditions. Depression support is a phone call away – call 866-478-4383 to learn about our current treatment options.
See our residences in Southern California’s Orange County & San Diego County.
Take a look at our homes on the east side of the Metro area in Washington County.
View our facilities in Fairfax County, VA within the DC metro area.
If what you’ve read on this page has made you wonder if there are options you haven’t explored yet, seeking another perspective could be a positive step.
Living with depression that hasn’t responded to standard treatment is exhausting, and staying with a plan that has stopped producing results costs you time that could be spent finding something that works.
AMFM Treatment provides mental health care for adults dealing with conditions like depression, but also other conditions that could be underlying, including:
Our compassionate clinical team is experienced in working with complex and treatment-resistant presentations and can tailor your care to where you are right now rather than starting from scratch, so you can achieve lasting, life-changing outcomes.
We offer residential programs for those who need the structure of a full-time therapeutic environment. We also provide intensive outpatient options for those who need flexible support around daily life.
Our locations in California, Minnesota, and Virginia accept insurance and are in-network with most major providers. To check your insurance coverage for mental health care, simply complete our confidential online verification form. A caring member of our team will reach out to you to go over your benefits and treatment options.
If you’re looking for a full diagnostic reassessment or maybe a second opinion on a treatment plan that hasn’t been working, our admissions team can help you work out what the right next step looks like. Call us today at 866-478-4383.
100% Confidential
No Commitment
Instant Results
At AMFM, we strive to provide the most up-to-date and accurate medical information based on current best practices, evolving information, and our team’s approach to care. Our aim is that our readers can make informed decisions about their healthcare.
Our reviewers are credentialed medical providers specializing and practicing behavioral healthcare. We follow strict guidelines when fact-checking information and only use credible sources when citing statistics and medical information. Look for the medically reviewed badge on our articles for the most up-to-date and accurate information.
If you feel that any of our content is inaccurate or out of date, please let us know at info@amfmhealthcare.com
